Sarah Waliany/LinkedIn
Jul 15, 2025, 01:19
Sarah Waliany: Dynamic Debate on 1L Combos vs 1L Osimertinib for EGFR+ NSCLC
Sarah Waliany, Clinical Fellow in Hematology/Oncology at Dana-Farber Cancer Institute, shared a post on X:
“Dynamic debate between Julia Rotow and Benjamin Besse on 1L combos vs 1L Osimertinib for EGFR+ NSCLC
- FLAURA2 and MARIPOSA more effective for most subgroups than osi alone: highly important for patients with increased risk features
- Significant tox of MARIPOSA: need for mitigation (subQ ami, COCOON ppx).”
More posts featuring Osimertinib.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 7, 2025, 16:01
Aug 7, 2025, 15:18
Aug 7, 2025, 14:35